Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPTela adjuvant elacestrant versus standard endocrine therapy in high-risk ER-positive/HER2-negative early breast cancer
2025-522484-15-00Phase 3Authorised
- Sponsor
- Westdeutsche Studiengruppe
- Start
- Apr 2026
- Modality
- Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of elacestrant and ribociclib in breast cancer (2 arms), sponsored by Westdeutsche Studiengruppe. Primary endpoint: Invasive disease-free survival. Planned start Apr 2026; status: authorised.
02
Drugs
elacestrantribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-522484-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522484-15-00.